Polymorphism of MMP1 and MMP3 promoter regions and HR-HPV infection in women from Burkina Faso and Côte d'Ivoire.


Journal

Biomolecular concepts
ISSN: 1868-503X
Titre abrégé: Biomol Concepts
Pays: Germany
ID NLM: 101518829

Informations de publication

Date de publication:
17 05 2020
Historique:
received: 02 03 2020
accepted: 01 04 2020
entrez: 18 5 2020
pubmed: 18 5 2020
medline: 26 11 2020
Statut: epublish

Résumé

The single nucleotide polymorphism (SNP) of the promoter region of MMP-1 (at 1607 bp) and MMP-3 (at 1171 bp) create Ets binding sites. Correlations between these SNPs and sensitivity to several biological processes such as metastasis and recurrence of cancer have been reported in several studies. In this case-control study, we looked for these SNPs in women infected with or not with high-risk human papillomaviruses (HR-HPV). The frequency, distribution and correlation of these SNPs with the presence or absence of HR-HPV infection were evaluated. Genotypes 1G1G, 1G2G and 2G2G for MMP1 and genotypes 5A5A, 5A6A, 6A6A for MMP3 were found in our study population. In general, we noted that the 1G (40.8%) and 2G (64.8%) alleles were more frequent in non-infected women and infected women, respectively, and more specifically this difference was significant in women from Côte d'Ivoire. These results, although yet to be reaffirmed with assays for quantifying the mRNA of these genes, suggest that the SNP of the MMP-1 promoter could promote infection with HR-HPV.

Identifiants

pubmed: 32417757
doi: 10.1515/bmc-2020-0010
pii: /j/bmc.2020.11.issue-1/bmc-2020-0010/bmc-2020-0010.xml
doi:
pii:

Substances chimiques

MMP3 protein, human EC 3.4.24.17
Matrix Metalloproteinase 3 EC 3.4.24.17
MMP1 protein, human EC 3.4.24.7
Matrix Metalloproteinase 1 EC 3.4.24.7

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

116-124

Commentaires et corrections

Type : ErratumIn

Auteurs

Prosper Bado (P)

Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, 03 BP 7021 Ouagadougou 03, Ouagadougou Burkina Faso.
Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364 Ouagadougou 01, OuagadougouBurkina Faso.

Florencia Djigma Wendkuuni (F)

Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, 03 BP 7021 Ouagadougou 03, Ouagadougou Burkina Faso.
Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364 Ouagadougou 01, OuagadougouBurkina Faso.

Mahoukèdè Zohoncon Théodora (M)

University Saint Thomas d'Aquin, Faculty of Medicine, 06 BP 10212 Ouagadougou 01, Ouagadougou Burkina Faso.

Dorcas Obiri-Yeboah (D)

University of Cape Coast, School of Medical Sciences, Department of Microbiology and Immunology, University Post Office, Cape Coast Ghana.

Alima Traoré Esther Mah (A)

Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, 03 BP 7021 Ouagadougou 03, Ouagadougou Burkina Faso.
Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364 Ouagadougou 01, OuagadougouBurkina Faso.

Karim Ouattara Abdoul (K)

Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, 03 BP 7021 Ouagadougou 03, Ouagadougou Burkina Faso.
Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364 Ouagadougou 01, OuagadougouBurkina Faso.

Clarisse Ouedraogo Teega-Wendé (C)

Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, 03 BP 7021 Ouagadougou 03, Ouagadougou Burkina Faso.

Toyin Bello Shoukrat Ohuwa (T)

Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, 03 BP 7021 Ouagadougou 03, Ouagadougou Burkina Faso.

Ayaovi Setor Marius (A)

Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, 03 BP 7021 Ouagadougou 03, Ouagadougou Burkina Faso.

Angèle Traore Ina Marie (A)

Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, 03 BP 7021 Ouagadougou 03, Ouagadougou Burkina Faso.
Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364 Ouagadougou 01, OuagadougouBurkina Faso.

Apollinaire Horo (A)

University Félix Houphouët Boigny, Abidjan Medical Sciences Training and Research Unit, 01 BPV 34 Abidjan 01, Abidjan Côte d'Ivoire.

Privat Kouakou Kouame (P)

Université Alassane Ouattara, Bouaké, Hôpital Catholique Saint Joseph Moscati 01 BP 1107 Yamoussoukro Côte d'Ivoire.

Théophane Yonli Albert (T)

Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, 03 BP 7021 Ouagadougou 03, Ouagadougou Burkina Faso.
Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364 Ouagadougou 01, OuagadougouBurkina Faso.

Charlemagne Ouedraogo (C)

University Joseph Ki-Zerbo, UFR/SDS, 03 BP 7021 Ouagadougou 03, Ouagadougou Burkina Faso.

Jacques Simpore (J)

Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, 03 BP 7021 Ouagadougou 03, Ouagadougou Burkina Faso.
Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364 Ouagadougou 01, OuagadougouBurkina Faso.
University Saint Thomas d'Aquin, Faculty of Medicine, 06 BP 10212 Ouagadougou 01, Ouagadougou Burkina Faso.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH